Invus Public Equities Advisors, LLC
CIK 1340096 · last filed 2024-08-09
Invus Public Equities Advisors, LLC is a corporate insider who has filed 6 SEC Form 4 insider transactions across 2 companies since 2014. The most recent filing shows the insider sold $306.0K of GLYC on Aug 9, 2024. Across all open-market trades the lifetime net is +$1.65B, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $40.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$40.94M
2
6
$1.65B
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | 10%+ Owner | 6,317,565 | $15.70 | $99.19M | -$306.0K | 1 | 2024-08-09 |
| LXRX | Director | 21,321,961 | $1.92 | $40.94M | $1.65B | 5 | 2018-06-29 |
Recent Filings
6 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-08-09 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Sell (S) | −1,611,805 | -$306.0K | EDGAR |
| 2018-06-29 | LXRX | Buy (P) | +1,828,380 | $22.87M | EDGAR |
| 2018-06-12 | LXRX | Buy (P) | +2,353,960 | $30.14M | EDGAR |
| 2018-06-07 | LXRX | Buy (P) | +3,256,390 | $40.95M | EDGAR |
| 2017-11-14 | LXRX | Buy (P) | +5,759,460 | $55.54M | EDGAR |
| 2014-11-26 | LXRX | Buy (P) | +1,492,537,310 | $1.50B | EDGAR |